Skip to main content

LCD L37794: MolDX: Breast Cancer Index® (BCI) Gene Expression Test

LCD L37794, MolDX: Breast Cancer Index® (BCI) Gene Expression Test, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2025-07-03 and first in force 2019-03-11. The policy text runs 159 words, and its billing and coding article A56875 lists 17 ICD-10-CM codes that support medical necessity for 1 procedure code. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 17 covered ICD-10-CM codes: the same total as L37822 (Noridian Healthcare Solutions, LLC, 17 codes, revised 2026-01-22) and the same total as L37832 (CGS Administrators, LLC, 17 codes, revised 2025-10-23).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2025-07-03
Original effective
2019-03-11
Policy text
159 words
Covered ICD-10 codes (articles)
17

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L37794
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56875: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56875 (Billing and Coding: MolDX: Breast Cancer Index® (BCI) Gene Expression Test) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A56875: Billing and Coding: MolDX: Breast Cancer Index® (BCI) Gene Expression Test (Billing and Coding, effective 2021-10-09)

Covered ICD-10-CM codes
17
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 17 covered ICD-10-CM codes in A56875
ICD-10-CMDescription (FY2027)
C50.011Malignant neoplasm of nipple and areola, right female breast
C50.012Malignant neoplasm of nipple and areola, left female breast
C50.111Malignant neoplasm of central portion of right female breast
C50.112Malignant neoplasm of central portion of left female breast
C50.211Malignant neoplasm of upper-inner quadrant of right female breast
C50.212Malignant neoplasm of upper-inner quadrant of left female breast
C50.311Malignant neoplasm of lower-inner quadrant of right female breast
C50.312Malignant neoplasm of lower-inner quadrant of left female breast
C50.411Malignant neoplasm of upper-outer quadrant of right female breast
C50.412Malignant neoplasm of upper-outer quadrant of left female breast
C50.511Malignant neoplasm of lower-outer quadrant of right female breast
C50.512Malignant neoplasm of lower-outer quadrant of left female breast
C50.611Malignant neoplasm of axillary tail of right female breast
C50.612Malignant neoplasm of axillary tail of left female breast
C50.811Malignant neoplasm of overlapping sites of right female breast
C50.812Malignant neoplasm of overlapping sites of left female breast
Z17.0Estrogen receptor positive status [ER+]

Procedure codes: 81518.

Coverage indications, limitations and medical necessity

This Medicare contractor will provide limited coverage for the Breast Cancer Index® (BCI) gene expression test (Biotheranostics, Inc., San Diego, CA). The BCI test is used by physicians to provide a genomic-based estimate of distant recurrence risk when considering addition of chemotherapy, and/or late distant recurrence risk and endocrine responsiveness when considering extension of endocrine therapy, depending upon when in the continuum of care testing is requested.

The BCI test is covered for postmenopausal women with invasive breast cancer when the following criteria are met:

• Pathology reveals invasive carcinoma of the breast that is estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) and Human Epidermal Growth Factor Receptor 2 negative (HER2-); and

• Patient has early-stage disease {Tumor, Node, Metastasis (TNM) stage T1-3, pN0-N1, M0}; and

• Patient has no evidence of distant breast cancer metastasis (i.e., non-relapsed); and

• Test results will be used in determining treatment management of the patient for chemotherapy and/or endocrine therapy.

Summary of evidence (opening)

Adjuvant therapy decisions initially and at 5 years in ER+ (or PR+)/HER2- node negative breast cancer

In 2017, approximately 253,000 patients were expected to be diagnosed with invasive breast cancer in the United States, 1 of which approximately 90% are diagnosed with early-stage disease. Hormone-receptor positive (HR+) breast cancer is the most common subtype of breast cancer (~80% of cases 1 ) and has the most favorable prognosis overall. 1 Standard-of-care treatment for HR+ disease includes primary adjuvant anti-estrogen therapy with tamoxifen, an aromatase inhibitor (AI), or a sequence of these. In addition to anti-estrogen therapy, 2 key treatment decisions are priorities in the management of early stage breast cancer. The first decision is whether the patient is of sufficient risk of recurrence to recommend systemic adjuvant chemotherapy. In addition, while HR+ early-stage breast cancer patients have a favorable prognosis overall, there is an ongoing risk of distant recurrence (DR) beyond year 5 (late recurrence), and 75% of deaths occur more than 5 years post-diagnosis. As such, the second key decision is whether to recommend extension of endocrine therapy beyond the initial primary adjuvant therapy. For each treatment decision, physicians and patients must weigh whether the potential benefit from the additional treatment regimen is likely to outweigh the risks of serious toxicities and side effects.

Improving Patient Stratification for Addition of Adjuvant Chemotherapy

Adjuvant chemotherapy has been shown to improve outcomes in patients with early stage HR+ breast cancer. In a meta-analysis of 100,000 women across 123 randomized trials, 2 the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported that patients with early-stage breast cancer experience an approximately 30% reduction in DR rate or benefit from adjuvant chemotherapy. Notably, this analysis also showed that proportional risk reduction was not affected by traditional clinical and pathologic factors (e.g., nodal status, tumor size, tumor grade). Patients, therefore, with a limited underlying risk of DR will have a lower absolute benefit from chemotherapy, compared to patients with a high underlying risk of DR. For each patient, the expected absolute benefit of chemotherapy needs to be weighed against the 2-3% chance of fatal, life-threatening, or life-changing toxicities. 3

The contractor cites 21 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2019-03-11
Current revision effective
2025-07-03
Last reviewed by the contractor
2025-05-08
MCD version
23

Other related documents: A58629 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L37794 cover?

This Medicare contractor will provide limited coverage for the Breast Cancer Index® (BCI) gene expression test (Biotheranostics, Inc., San Diego, CA). The BCI test is used by physicians to provide a genomic-based estimate of distant recurrence risk when considering addition of chemotherapy, and/or late distant recurrence risk and endocrine responsiveness when considering extension of endocrine therapy, depending… The full 159-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L37794 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L37794?

The companion billing and coding article A56875 lists 17 ICD-10-CM codes in 1 group that support medical necessity; the first 17 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L37794?

A denial under LCD L37794 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56875's 17 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.